The aim of this study was to determine whether cAMP signal transduction plays a role in the regulation of endothelial nitric oxide (NO) production. Canine coronary blood vessels were isolated, and nitrite, the hydration product of NO, from these vessels was quantified by using the Griess reaction. Forskolin (10 Ϫ4 mol/L), 8-bromo-cAMP (10 Ϫ2 mol/L), or isoproterenol (10 Ϫ4 mol/L) significantly increased nitrite release to 168Ϯ10, 162Ϯ13, or 149Ϯ13 pmol/mg, respectively, from isolated coronary microvessels (all PϽ0.05; control, 86Ϯ3 pmol/mg). Adrenomedullin and calcitonin gene-related peptide (CGRP), both potent vasodilator peptides, also increased coronary microvascular nitrite production. N -nitro-L-arginine methyl ester, a competitive inhibitor of NO synthase, or Rp-cAMP, a protein kinase A inhibitor, markedly blocked the nitrite release induced by these agents. Forskolin and adrenomedullin also potentiated coronary NO production induced by bradykinin. In large coronary arteries, removal of the endothelium eliminated nitrite production to both forskolin and acetylcholine. Our data demonstrate that stimulation of cAMP signal transduction can substantially increase coronary NO production, indicating that there is a cAMP-mediated, endothelial NO-forming system in coronary blood vessels. Because the cAMP signal cascade can be activated by CGRP or adrenomedullin and enhance kinin-mediated nitrite production, the cAMP-NO pathway may play an important role in the regulation of cardiovascular function. (Arterioscler Thromb Vasc Biol. 2001;21:797-803.) Key Words: cAMP Ⅲ nitric oxide Ⅲ endothelium Ⅲ protein kinase B Ⅲ coronary blood vessels
␤ -Adrenoceptor agonists and adenosine have been regarded as "archetypal" endothelium-independent vasodilators that cause vasodilation by increasing intracellular cAMP, with subsequent activation of protein kinase A (PKA) and myosin light-chain kinase within smooth muscle cells. [1] [2] [3] [4] [5] [6] However, recent studies have challenged this concept. Growing evidence indicates that a number of classic endotheliumindependent vasodilator drugs also cause endotheliumdependent vasodilation, and this process seems to be related to endothelial NO production. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] These include (1) the inhibition of isoprenaline-induced vasorelaxation in rat aorta by hemoglobin and methylene blue 11, 12 ; (2) the inhibition of prostacyclin-and forskolin-induced vasorelaxation in pig coronary artery in vitro by hemoglobin and methylene blue 13 ;
(3) the inhibition of salbutamol-and epinephrine-induced vasorelaxation in vivo and in vitro in the rat by the NO synthase (NOS) inhibitor N -nitro-L-arginine methyl ester (L-NAME); 14 -16 (4) the inhibition of isoproterenol-induced resistance coronary vessel dilation in the conscious dog by L-NAME 17, 18 ; and (5) the inhibition of isoproterenol-induced vasodilation in human forearm by N -monomethyl-Larginine. 19 These results indicate that in blood vessels, there is an NO component to the vasorelaxant response to all of See page 729 these agonists. This may be of particular physiological importance because many endogenous factors that affect cAMP production, such as ATP or adenosine, 20, 21 norepinephrine or epinephrine, 22 and adrenomedullin or calcitonin gene-related peptide (CGRP), 23, 24 may therefore participate in the regulation of endothelial NO production. Indeed, studies by Graier et al 25 and Li et al 26 have found that adenosine significantly enhances basal or agonist-induced NO release from cultured porcine artery endothelial cells. Kanai et al 22 also found that norepinephrine and epinephrine evoke detectable NO release from individual rat ventricular myocytes. However, the mechanism of NO formation from blood vessels induced by these cAMP-elevating agents remains unknown. Therefore, our study was designed to determine (1) whether stimulation of the cAMP signaltransduction pathway can increase endothelial NO production from coronary blood vessels; (2) whether there is a natural ligand of the cAMP-NO pathway in coronary microvessels from normal dog heart; (3) whether stimulation of cAMP signal transduction can affect kinin-mediated NO formation; and (4) whether this mechanism is endothelium dependent.
Methods

Animal Preparation
All of the studies were approved by the institutional Animal Care and Use Committee of New York Medical College and conform to current National Institutes of Health and American Physiological Society guidelines for the use and care of laboratory animals. Twenty-nine adult mongrel dogs (body weight 21 to 29 kg) were anesthetized with pentobarbital (IV, 50 mg/kg). The heart was excised immediately and kept in ice-cold PBS containing 0.1% bovine serum albumin at pH 7.4.
Isolation of Coronary Microvessels and Large Coronary Arteries
Isolation of coronary microvessels from the left ventricular free wall of the dog heart was performed with the method used in previous studies. 27, 28 Coronary microvessels were obtained after separation from large arteries and veins, connective tissue, fat, and myocytes by a series of steps involving sequential dissection, homogenization, sieving, and glass bead purification. This preparation of microvessels (diameter range 20 to 70 m) was virtually free of myocytes and consisted only of arterioles, venules, and capillaries. Approximately 2000 mg of microvessels was collected per heart (215Ϯ7 g). The left circumflex, left anterior descending, or right coronary artery from 7 dogs was removed and cut into rings (Ϸ20 mg in weight). To determine the role of the endothelium in NO production from cardiac blood vessels, from some coronary artery rings the endothelium was denuded by scraping with a wooden stick.
Incubation of Coronary Microvessels and Large Coronary Arteries
Microvessels, Ϸ20 mg (wet weight) of tissue, were oxygenated with 95% O 2 and 5% CO 2 in PBS for 30 minutes, placed in 5-mL plastic tubes that contained chemical stimuli or inhibitors, and incubated for 20 minutes at 37°C. At the end of the incubation time, the tubes were removed from the tissue bath, and sulfanilamide (450 L of a 1% solution) and N-(1-naphthyl)ethylenediamine (50 L of a 0.2% solution) were added to each tube for diazotization of sulfanilic acid by NO. After 5 to 10 minutes' incubation at room temperature for full color (pink) development, the supernatant was removed from each tube. Formation of NO was measured as nitrite. Nitrite release was measured with a spectrophotometer (Uvikon 930 spectrophotometer, Kontron Instruments Inc) as the increase in absorbance at 540 nm and compared with known concentrations of nitrite. Absorbance was measured and converted to a straight line by use of linear regression analysis (yϭaxϩb, RϾ0.99). Coronary artery rings were incubated in a fashion similar to microvessels. We have described these methods recently. 27, 28 
Method to Dissect cAMP-NO Transduction
After stimulation of cAMP in microvessels with the use of agonists (ie, forskolin, an adenylyl cyclase activator; isoproterenol, a ␤-adrenoceptor agonist; and adrenomedullin and CGRP, both activators of adenylyl cyclase), we used a number of inhibitors to determine the signal-transduction pathway leading to NO formation. L-NAME was used to block NOS to ensure that nitrite release was indicative of NO formation. 8-Bromo-cAMP (a membranepermeable cAMP analogue) was used to bypass adenyl cyclase. Dideoxyadenosine, a specific inhibitor (10 Ϫ4 mol/L), was used to block the effect of adenyl cyclase. Rp-cAMP is a selective potent inhibitor of protein kinase A, and 10 Ϫ3 mol/L Rp-cAMP is a common concentration used to inhibit protein kininase A. LY294002 is a specific inhibitor of phosphatidylinositol 3-kinase (PI3 kinase). We used LY294002 at a concentration of 3ϫ10 Ϫ5 mol/L to inhibit this enzyme. Wortmannin is a less-specific inhibitor than is LY294002 for PI3 kinase, and 10 Ϫ7 mol/L wortmannin was used in this study to block the effect of PI3 kinase. Propranolol, a nonselective ␤-adrenoceptor inhibitor (10 Ϫ4 mol/L), was used to block the stimulatory effect of ␤-adrenoceptor on adenyl cyclase.
Experimental Protocols
Effects of Forskolin, 8 Bromo-cAMP, and Isoproterenol on cAMP Signal Transduction-Mediated NO Production in Coronary Microvessels
Increasing concentrations of forskolin (10 Ϫ10 to 10 Ϫ4 mol/L), 8-bromo-cAMP (10 Ϫ8 to 10 Ϫ2 mol/L), and isoproterenol (10 Ϫ10 to 10 Ϫ4 mol/L) were incubated with tissue for 20 minutes. Nitrite release was measured. L-NAME (10 Ϫ4 mol/L), Rp-cAMP (10 Ϫ3 mol/L), dideoxyadenosine (10 Ϫ4 mol/L), LY294002 (3ϫ10 Ϫ5 mol/L), wortmannin (10 Ϫ7 mol/L), or propranolol (10 Ϫ4 mol/L) was also incubated with tissue before addition of the highest concentration of forskolin, 8-bromo-cAMP, or isoproterenol.
Effects of Adrenomedullin and CGRP on cAMP Signal Transduction-Mediated NO Production in Coronary Microvessels
Increasing concentrations of adrenomedullin and CGRP (10 Ϫ12 to 10 Ϫ6 mol/L) were incubated with tissue for 20 minutes. Nitrite release was measured. L-NAME (10 Ϫ4 mol/L), Rp-cAMP (10 Ϫ3 mol/L), dideoxyadenosine (10 Ϫ4 mol/L), LY294002 (3ϫ10 Ϫ5 mol/L), wortmannin (10 Ϫ7 mol/L), or propranolol (10 Ϫ4 mol/L) was also incubated with tissue before addition of the highest concentration of adrenomedullin or CGRP.
Effects of Forskolin and Adrenomedullin on NO Production Induced by Bradykinin
The effects of forskolin and adrenomedullin on nitrite production induced by bradykinin were studied. Increasing concentrations of bradykinin (10 Ϫ10 to 10 Ϫ5 mol/L), alone and in the presence of a subthreshold concentration (a low concentration that has no effect on NO production) of forskolin (10 Ϫ10 mol/L) or adrenomedullin (10 Ϫ12 mol/L), were incubated with tissue for 20 minutes. Nitrite was measured. L-NAME (10 Ϫ4 mol/L), HOE 140 (Icatibant, a specific B 2 -kinin receptor antagonist; 10 Ϫ5 mol/L [Hoechst]), Rp-cAMP (10 Ϫ3 mol/L), or dideoxyadenosine (10 Ϫ4 mol/L) was also incubated with tissue before addition of the highest concentration of bradykinin combined with forskolin or adrenomedullin.
Role of Endothelium in Forskolin-or Acetylcholine-Mediated NO Production in Large Coronary Arteries
Increasing concentrations of forskolin (10 Ϫ9 to 10 Ϫ4 mol/L) or acetylcholine (10 Ϫ8 to 10 Ϫ5 mol/L) were incubated with large coronary arteries with or without endothelium for 20 minutes. Nitrite release was measured. L-NAME (10 Ϫ4 mol/L), Rp-cAMP (10 Ϫ3 mol/L), or atropine (10 Ϫ5 mol/L) was also incubated with tissue before addition of the highest concentration of forskolin or acetylcholine.
Drugs and Chemicals
The PBS used in these studies consisted of (in mmol/L) NaCl 139, KCl 2.7, NaH 2 PO 4 8.1, KH 2 PO 4 1.5, CaCl 2 0.68, and MgCl 2 0.49; bovine serum albumin concentration was 0.1%. Drugs (adrenomedullin, CGRP, acetylcholine, and bradykinin) and chemicals (8-bromo-cAMP, isoproterenol, L-NAME, dideoxyadenosine, LY294002, wortmannin, propranolol, nitrite, and bovine serum albumin) were purchased from Sigma Chemical Co. Forskolin was purchased from Calbiochem-Novabiochem Corp. Rp-cAMP was purchased from Research Biochemicals International.
Statistical Analysis and Calculations
To construct a standard curve for nitrite, a stock solution of NaNO 2 (10 Ϫ5 mol/L) was prepared and diluted for each experiment. Sulfanilamide (450 L of a 1% solution) and N-(1-naphthyl)ethylenediamine (50 L of a 0.2% solution) were mixed with NaNO 2 and allowed to stand at room temperature for 5 to 10 minutes for full color (pink) development. Absorbance of nitrite was measured at 540 nm and converted to a straight line by using regression analysis (yϭaxϩb, RϾ0.99). Nitrite production was calculated with the linear regression formula. Data were expressed as meanϮSEM in pmol/mg wet weight per 20 minutes. Differences in nitrite production versus control were determined with a 2-way ANOVA. The differences between individual data points were determined with Tukey's test. PϽ0.05 was considered statistically significant. After combining bradykinin with forskolin or adrenomedullin, the change in nitrite, which was statistically greater than that obtained by simply adding the changes in nitrite induced by each drug alone, was considered a synergistic effect. Statistical analysis and graphs were produced on a Pentium II computer (Dell) and commercially available software (Lotus 1,2,3; Sigmastat; Slide Write).
Results
Data in the figures are the changes in nitrite production in pmol/mg wet weight per 20-minute incubation, whereas data in the text are percentages of the change in nitrite and absolute values.
Effects of Forskolin, 8-Bromo-cAMP, and Isoproterenol on cAMP Signal Transduction-Mediated NO Production in Coronary Microvessels
Forskolin (10 Ϫ10 to 10 Ϫ4 mol/L), 8-bromo-cAMP (10 Ϫ8 to 10 Ϫ2 mol/L), and isoproterenol (10 Ϫ10 to 10 Ϫ4 mol/L) concentration-dependently increased nitrite production by 15Ϯ5% to 98Ϯ8%, 20Ϯ4% to 103Ϯ11%, and 17Ϯ3% to 78Ϯ11%, respectively (from a control value of 85Ϯ3 pmol/ mg; all PϽ0.05) The actual changes in nitrite are shown in Figure 1 . After incubation with L-NAME, Rp-cAMP, dideoxyadenosine, LY294002, and wortmannin, nitrite release induced by the highest concentration of forskolin, 8-bromo-cAMP, or isoproterenol was reduced by 90% to 100%, 32% to 88%, and 95% to 100%, respectively (all PϽ0.01). Propranolol entirely eliminated the effects of isoproterenol. The effects of these antagonists (except propranolol) on the actual changes in nitrite induced by forskolin, 8-bromo-cAMP, and isoproterenol are shown in Figure 2 .
Effects of Adrenomedullin and CGRP on cAMP Signal Transduction-Mediated NO Production in Coronary Microvessels
The effects of adrenomedullin and CGRP on NO production are shown in Figure 3 . Adrenomedullin (10 Ϫ12 to 10 Ϫ6 mol/L) and CGRP (10 Ϫ12 to 10 Ϫ6 mol/L) increased nitrite production by 18Ϯ7% to 86Ϯ17% and by 19Ϯ7% to 98Ϯ16%, respectively (from a control value of 84Ϯ3 pmol/mg; all PϽ0.05). After incubation with L-NAME, Rp-cAMP, dideoxyadenosine, LY294002, or wortmannin, nitrite release induced by the highest concentration of adrenomedullin or CGRP was blocked by 70% to 100% and by 80% to 100%, respectively (all PϽ0.01). The effects of these antagonists on the actual changes in nitrite induced by adrenomedullin or CGRP are shown in Figure 4 .
Effects of Forskolin and Adrenomedullin on NO Production Induced by Bradykinin
Bradykinin (10 Ϫ10 to 10 Ϫ5 mol/L) concentration-dependently increased nitrite release by 14Ϯ4% to 95Ϯ21% (from a control value of 81Ϯ3 pmol/mg). After incubation with a low concentration of forskolin (10 Ϫ10 mol/L) or adrenomedullin (10 Ϫ12 mol/L), nitrite release induced by increasing concentrations of bradykinin was elevated by 51Ϯ8% to 171Ϯ10% and by 66Ϯ3% to 168Ϯ12%, respectively. Comparison of the effects of the highest concentrations of bradykinin showed that forskolin and adrenomedullin potentiated the change in nitrite production by 34% and 39% (PϽ0.05 vs bradykinin alone), respectively. These effects were synergistic. The effect of forskolin on nitrite production induced by bradykinin is shown in Figure 5 . In the presence of L-NAME, HOE 140, Rp-cAMP or dideoxyadenosine, the effects of forskolin and adrenomedullin on nitrite release induced by the highest concentration of bradykinin were blocked by 83% to 99%, respectively (all PϽ0.01).
Role of Endothelium in Forskolin-or Acetylcholine-Mediated NO Production in Large Coronary Arteries
Forskolin (10 Ϫ9 to 10 Ϫ4 mol/L) and acetylcholine (10 Ϫ8 to 10 Ϫ5 mol/L) concentration-dependently increased nitrite production from large coronary arterial rings by 7Ϯ4% to 105Ϯ22% and by 4Ϯ3% to 87Ϯ13%, respectively (from a control value of 81Ϯ8 pmol/mg; all PϽ0.05). After incubation with L-NAME or Rp-cAMP, nitrite release induced by the highest concentration of forskolin was reduced by 87% or 85%, respectively (all PϽ0.01). After incubation with L-NAME or atropine or denudation of the endothelium, nitrite release induced by the highest concentration of acetylcholine was blocked by 95% and 96%, respectively (all PϽ0.01). After denudation of the endothelium, neither forskolin nor acetylcholine had an effect on nitrite production (all PϾ0.05).
The actual changes in nitrite production in response to forskolin are shown in Figure 6 .
Discussion
The most important finding in the present study is that stimulation of cAMP signal transduction can significantly increase NO formation from isolated canine coronary blood vessels. This effect is mediated by PKA and PI3 kinase. Two endogenous vasodilators, adrenomedullin and CGRP, also substantially increased coronary NO production via stimulation of cAMP signal transduction, indicating that there is an innate cAMP-NO pathway in coronary blood vessels. Another significant finding in this study is that stimulation of cAMP signal transduction by forskolin or adrenomedullin dramatically potentiated coronary vascular NO production induced by bradykinin, indicating synergism between kininmediated endothelial NO production and intracellular cAMP signal transduction. Because forskolin-induced NO production was eliminated by prior endothelium denudation in large coronary arteries, our results suggest the concept that coronary cAMP signal transduction may participate in the regulation of cardiovascular endothelial NO production.
NO, a potent vasodilator, has been identified as a major endothelium-derived relaxing factor synthesized by NOS in the endothelium. 1-3 A number of physiological factors, such as shear stress, or vasoactive substances, such as acetylcholine and bradykinin, regulate NO production from endothelial cells. 2,3 ␤-Adrenoceptor agonists or adenosine are widely believed to be another group of potent vasodilators that cause endothelium-independent vasodilation by a different second messenger, ie, cAMP, in smooth muscle. [1] [2] [3] [4] [5] [6] However, recent studies suggest that vascular relaxant responses to many adenylate cyclase activators are, at least in part, also endothelium dependent. In our study, stimulating ␤-adrenoceptors by isoproterenol, activating adenylyl cyclase by forskolin, or activating PKA by 8-bromo-cAMP all evoked significant NO release from isolated coronary microvessels. The NOS inhib- itor L-NAME substantially blocked these effects, strongly supporting the concept that coronary microvessels produce NO in response to all of these stimuli by activating NOS. Removal of the endothelium in coronary microvessels (diameter Ϸ20 to 70 m) is very difficult. So we tested whether removal of the endothelium would alter NO production in large epicardial coronary arteries in response to forskolin and acetylcholine. Mechanical removal of the endothelium abolished nitrite release in response to forskolin, suggesting that nitrite seems to be of endothelial origin. These data support our concept that endothelial NO production is enhanced by stimulation of cAMP. Because production of NO induced by all of these cAMP-increasing agents reached a level similar to that induced by bradykinin and acetylcholine 28, 29 in coronary microvessels, we suggest that cAMP-mediated coronary NO production may contribute to coronary vasodilation.
␤-Adrenoceptors are present on endothelial cells 30 -32 and are linked to the activation of adenylyl cyclase. 22, 25, 33, 34 In the present study, dideoxyadenosine blocked the effects of forskolin and isoproterenol on NO formation but did not affect nitrite release induced by 8-bromo-cAMP, indicating a specific inhibitory effect of dideoxyadenosine on adenylyl cyclase. These results suggest that forskolin or isoproterenol promotes NO production through activation of adenylyl cyclase. Propranolol also inhibited the effect of isoproterenol on NO production, suggesting that isoproterenol induces NO release by stimulating ␤-adrenoreceptors. Increasing the activity of adenylyl cyclase could subsequently increase intracellular cAMP, which may occur in both smooth muscle cells and the endothelium. [1] [2] [3] 35 However, a study by Gray and Marshall 15 found that in rat aortic rings, isoprenaline and forskolin increased cAMP accumulation in the endothelium but not in smooth muscle cells. It has been suggested that a rise in intracellular cAMP may activate endothelial NOS (eNOS) either directly or indirectly and evoke NO cGMPmediated relaxation. 15, 36 In our present study, inhibition of cAMP-dependent protein kininase A with Rp-cAMP abrogated the NO release induced by isoproterenol, forskolin, and 8-bromo-cAMP, clearly showing an indirect effect of cAMP on NOS. It is generally accepted that in cell types other than vascular endothelial cells, stimulation by receptor-operated agonists evokes adenylyl cyclase activation by a G protein to produce cAMP. This acts in conjunction with cAMPdependent protein kininase A to induce calcium influx through voltage-gated calcium channels, resulting in an increase in intracellular calcium. However, it has been shown 31 that endothelial cells lack voltage-gated calcium channels. Even so, activation of PKA-mediated potentiation of NOS activity has been suggested by many studies. Iranami et al 34 found that the PKA inhibitor H-89 markedly inhibited endothelial NO-mediated relaxation induced by isoproterenol in rat aortic rings. Graier et al 25 also reported that inhibition of cAMP-dependent protein kininase A abolished the stimulatory effects of cAMP-elevating, agonist-induced NO biosynthesis in cultured porcine aortic endothelial cells. All of these data suggest a crucial role of protein kininase A in the stimulation of NO production mediated by cAMP.
A very recent study by Chen et al 36 found that AMPactivated protein kinase coimmunoprecipitates with cardiac eNOS and phosphorylates Ser-1177 to activate eNOS. In our experiments, a 20-minute incubation of all of the agents with isolated coronary microvessels significantly increased tissue NO release. The most probable explanation for this phenomenon is the increase in activity of the enzyme rather than an increase in expression of mRNA or protein for NOS. Our study also shows that the increased activity of NOS is unlikely to be mediated via phosphorylation by protein kininase A only, because 2 PI3 kinase inhibitors, LY294002 and wortmannin, also essentially abolished nitrite release induced by all of these agonists. These results indicate that PI3 kinase could be either a parallel or a downstream effector of protein kinase A on NOS. Importantly, 2 recent studies by Fulton et al 37 and Dimmeler et al 38 found that eNOS is an efficient substrate for PKB (serine/threonine protein kinase Akt). This enzyme can phosphorylate eNOS directly and increase its activity. This process is mediated by PI3 kinase. Taken together, their findings and our current results, it is interesting to speculate that the cAMP signal-transduction cascade increases coronary vascular NO release, perhaps via activation of PKA and subsequent phosphorylation of eNOS by PKB through a PI3 kinase-mediated mechanism.
A clinically significant finding in this study was that adrenomedullin and CGRP both markedly increased nitrite release from isolated canine coronary microvessels. It is thought that adrenomedullin induces vasorelaxation by activating adenylate cyclase and the subsequent increase in cAMP in vascular smooth muscle cells. 39 -44 Increasing evidence suggests that adrenomedullin also induces NO release from the endothelium. 23,40 -45 However, the intracellular signal-transduction pathway in the endothelium has never been addressed. CGRP, a vasodilator neuropeptide, is widely distributed in the autonomic nerve terminals supplying the cardiovascular system and is present in plasma. 24, 45, 46 Recent studies 24, 45, [47] [48] [49] have found that CGRP can also evoke endothelium-dependent and NO-mediated vasodilation. Adrenomedullin shares significant structural homology with CGRP. 23, 49 Both adrenomedullin and CGRP can increase intracellular cAMP in various tissues, including the endothelium. 15, 23 In the present study, both adrenomedullin and CGRP markedly increased NO production from isolated canine coronary microvessels, suggesting that coronary microvessels are capable of NO release in response to adrenomedullin and CGRP. L-NAME, Rp-cAMP, dideoxyadenosine, LY294002, and wortmannin significantly blocked this effect on NO formation, indicating that adrenomedullin and CGRP share a common mechanism with forskolin in NO formation, most likely by a cAMP-PKA and a PI3 kinaseregulated pathway. Both adrenomedullin and CGRP are endogenous biological factors. This may be of significant physiological or pathophysiological importance, because plasma adrenomedullin levels are elevated in a variety of disease states, including hypertension, congestive heart failure, and septic shock. 23,40 -42 Another important finding in our study is that forskolin and adrenomedullin both significantly potentiated coronary NO formation induced by bradykinin, suggesting a dual regulatory effect on NO production in the endothelium. Even a low physiological concentration of adrenomedullin (10 Ϫ12 mol/L, which alone has no significant effect on NO production) enhanced NO production induced by physiological concentrations of bradykinin (10 Ϫ10 to 10 Ϫ8 mol/L). NO production induced by bradykinin, after being combined with low concentrations of forskolin and adrenomedullin, was almost abolished not only by the NOS inhibitor and B 2 -kinin receptor antagonist but also by a PKA inhibitor and an adenylyl cyclase inactivator. Heart failure and many other cardiovascular diseases are associated with defective endothelial NO production. This has been recognized as an important pathophysiological mechanism. If stimulation of intracellular cAMP signal transduction promotes additional endothelial NO production, then cAMP-elevating agents may become a very useful tool for the treatment of many types of cardiovascular disease.
There are 2 limitations to our present study. First, we could not measure nitrite production from single endotheliumdenuded coronary microvessels. Therefore, the conclusion that an endothelium-dependent mechanism in coronary microvessels controls NO production induced by forskolin, based on evidence in large coronary arteries, is still speculative. Second, the specificity of some of the antagonists used in this study is uncertain. For example, we cannot eliminate a possible effect of Rp-cAMP and LY294002 on PKB directly, although according to the literature, Rp-cAMP and Ly294002 are very specific inhibitors for protein kininase A and PI3 kinase, respectively.
In summary, our data indicate that there is a cAMP-NO pathway in canine coronary blood vessels. Adrenomedullin or CGRP may be a natural ligand for activation of this signaltransduction system. Combining the stimulation of B 2 -kinin receptors and a cAMP signal system can have a synergistic effect on coronary NO production. Because a similar concentration of forskolin that was used in a recent study 50 could stimulate porcine coronary microvascular NO production and had a significant effect on NO-dependent coronary vasodilation and blood flow elevation, our data suggest that the cAMP-NO pathway may play a crucial role in the regulation of endothelium-dependent cardiac vascular function in physiological and pathophysiological states.
